lemonde.fr
Androcur Lawsuit Filed
A class action lawsuit targets Androcur, a drug linked to brain tumors, highlighting the delayed response from authorities and pharmaceutical companies.
French
France
Human Rights ViolationsHealthFranceLawsuitSafetyLiabilityMedication
AmaevaAnsm (Agence Nationale De Sécurité Du Médicament Et Des Produits De Santé)Caisse Nationale De L’assurance-MaladieEpi-Phare
Charles Joseph-Oudin
- What is the main focus of the class action lawsuit?
- A class action lawsuit has been filed against the makers of Androcur, a drug used to treat endometriosis, acne, and hair loss, due to its link to brain tumors (meningiomas) in hundreds of women.
- What are the alleged criminal offenses in the lawsuit?
- The lawsuit alleges five criminal offenses: administering a harmful substance, unintentional harm to a person, endangering others, failure to report adverse effects, and aggravated deception. The Amaeva association, representing victims, is leading the charge.
- What are the common experiences of the women affected by Androcur?
- Many women report that their gynecologists or endocrinologists prescribed Androcur without warning them about the risk of meningiomas. Symptoms like headaches and vision problems followed, leading to brain surgery and debilitating aftereffects.
- What criticism is leveled against the laboratory and health authorities?
- The lawsuit aims to hold accountable those responsible for the harm caused by Androcur, highlighting the need for greater transparency and responsibility from pharmaceutical companies and regulatory bodies regarding drug safety.
- How many women underwent surgery for meningiomas related to progestin medication between 2009 and 2018?
- Between 2009 and 2018, approximately 2,578 women underwent surgery for meningiomas linked to progestin medication. Expert reports consistently criticize the delayed response of the laboratory and health authorities, despite early warnings.